SciSparc Makes Important Progress in Tourette Syndrome Treatment
SciSparc Ltd. (Nasdaq: SPRC), a clinical-stage pharmaceutical company fully dedicated to addressing Tourette Syndrome (TS), is thrilled to share a major milestone. The company has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration, which signals the start of a Phase IIb clinical trial for its innovative drug candidate, SCI-110.
Where the Trial Will Be Held
This exciting study is set to occur at three esteemed centers of excellence: the Yale Child Study Center in the U.S., Hannover Medical School in Germany, and the Tel Aviv Sourasky Medical Center in Israel. The partnership among these renowned institutions aims to bolster the trial's credibility and thoroughness, and importantly, it has already received the go-ahead from the necessary ethics boards and health authorities.
Goals and Methods of the Trial
The principal aim of this Phase IIb trial is to comprehensively evaluate the efficacy, safety, and tolerability of SCI-110 in adult participants aged between 18 and 65. Participants will be randomly assigned to receive either SCI-110 or a matching placebo in a 1:1 ratio. To measure efficacy, researchers will track changes in tic severity using the well-known Yale Global Tic Severity Scale during evaluations at weeks 12 and 26 of the double-blind phase.
Safety and Efficacy Monitoring
Attention will also focus on safety, with close monitoring of the frequency and nature of serious adverse events reported in both treatment groups. This structured approach will help researchers gather essential data on the benefits and potential risks that come with SCI-110.
Learn More About SciSparc Ltd.
SciSparc Ltd. is not only dedicated to Tourette Syndrome; it also aims to develop a broader array of therapies targeting rare central nervous system disorders. The company is actively pursuing several promising drug programs, including SCI-110 for Tourette Syndrome, with a goal to enhance the lives of those impacted by TS while also investigating potential applications for Alzheimer’s disease and agitation.
Expanding Innovative Drug Development
Moreover, SciSparc is advancing its work on SCI-210, which is designed for Autism Spectrum Disorder (ASD) and status epilepticus. The company's commitment to cannabinoid pharmaceutical technologies places it at the forefront of innovative treatment options.
Engaging with Investors
The outlook for SciSparc remains bright as it continues to expand its impressive portfolio of technologies. The company also maintains a controlling interest in a subsidiary that markets hemp seed oil-based products on platforms like Amazon Marketplace. This varied strategy not only enhances the company's market presence but aligns with its mission to improve available therapies for a range of medical conditions.
Frequently Asked Questions
What is the purpose of SciSparc's Phase IIb trial?
The Phase IIb trial is designed to assess the efficacy, safety, and tolerability of the SCI-110 drug candidate in adults dealing with Tourette Syndrome.
Where will the clinical trial take place?
The clinical trial will be held at three prestigious locations: the Yale Child Study Center, Hannover Medical School, and Tel Aviv Sourasky Medical Center.
What are the primary measures for the trial?
The trial's primary measures include changes in tic severity tracked by the Yale Global Tic Severity Scale and monitoring for any adverse events.
What other conditions is SciSparc developing treatments for?
In addition to Tourette Syndrome, SciSparc is also focusing on creating therapies for Alzheimer’s disease, agitation, Autism Spectrum Disorder, and status epilepticus.
How can individuals contact the company for more information?
For any inquiries or further information, individuals can get in touch with SciSparc at IR@scisparc.com or by calling +972 3-761-7108.
